GlassScriptPhysician profile
David H Iansmith
NPI 1477585768
$5,339.86
in general payments reported to CMS, 2019-2025
28 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $447 · 2021: $1,099 · 2022: $951 · 2023: $667 · 2024: $715 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,171.98 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $484.62 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Philips North America LLC | $410.37 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Janssen Pharmaceuticals, INC | $404.04 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $400.74 | 2019-2022 | |
| Pfizer INC. | $303.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.02 | 2019-2025 | Jardiance |
| Amgen INC. | $219.22 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $217.40 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $183.19 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.84 | 2019-2022 | |
| Novo Nordisk INC | $144.34 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $143.16 | 2021-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals LP | $137.16 | 2019-2021 | |
| Biosense Webster, INC. | $121.07 | 2024-2025 | Carto 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $115.47 | 2019-2024 | Cardiomems |
| Akcea Therapeutics, INC. | $89.60 | 2019 | |
| Boston Scientific Corporation | $77.68 | 2024-2025 | Watchman Flx |
| Astellas Pharma US INC | $75.27 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $54.52 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $54.38 | 2022-2023 | Arcalyst |
| Inspire Medical Systems, INC. | $50.95 | 2023-2025 | Inspire |
| Esperion Therapeutics, INC. | $28.71 | 2021 | |
| Cvrx, INC. | $23.71 | 2023 | Barostim Neo System |
| Irhythm Technologies, INC. | $21.90 | 2024 | Zio Monitor, Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $17.54 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $16.05 | 2022 | |
| Altathera Pharmaceuticals LLC | $7.65 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Iansmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.